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Snipping away at the HIV pandemic, 
one foreskin at a time
Nearly two million South 
African (SA) men will have 
been voluntarily circum­
cised by the end of this year, 
about half of the govern­
ment’s original target – yet even this will 
have conservatively prevented 133 333 new 
HIV infections as a timely new public/pri­
vate sector initiative kicks in to boost overall 
efforts. In spite of this, alarm bells continue 
to ring as interventions for women, twice 
as vulnerable biologically and culturally, 
remain in various stages of trial.
Proven in field trials to reduce the risk 
of HIV infection by 60% and calculated 
to prevent one HIV infection for every 
5 - 15 men circumcised, voluntary medical 
male circumcision (VMMC) is uniquely suited 
to the SA environment, where 1 400 new HIV 
infections occur daily, the vast majority via 
heterosexual transmission. The latest private 
sector intervention comes from Metropolitan 
Health Risk Management, who have partnered 
with the Centre for HIV/AIDS Prevention 
Studies (CHAPS) and the National Department 
of Health in a bid to halve new HIV infections 
by next year – via VMMC scale-up. The ZAR55 
million United States Agency for International 
Development (USAID)-funded initiative is 
two-pronged: training or upskilling 850 general 
practi tioners, and increasing VMMC coverage 
in the private sector to 100 000 men per year 
by 2017. Since 2007, what was originally a 
Metropolitan Health and CHAPS initiative 
(government endorsed the programme in April 
this year) has resulted in 170 000 Metropolitan 
Health members being voluntarily circumcised. 
The private sector initiative uptake has slowly 
accelerated, from 12 000 in 2008 to 20 000 in 
2010, through 30 000 in 2012 to 45 000 last year. 
Mr Siraaj Adams, General Manager for HIV 
and TB at Metropolitan Health, said that the 
ZAR55 million was going towards the volun-
tary training of GPs by CHAPS at government 
facilities after their practices were identified 
according to HIV prevalence demographics 
(Johannesburg, Pretoria, Nelspruit, Uitenhage 
and Cape Town so far). By early June this year, 
a total of 150 GPs had undergone the rigorous 
training and been set up at their practices, 
where they were provided with free surgical 
circumcision packs and HIV test kits, and 
paid either the going medical aid rates for 
insured patients or a median medical aid rate 
by USAID for patients without cover. Doctors 
had to be covered for adverse events through 
medical practice insurance and earned ten 
continuing professional development (CPD) 
points after being ‘signed off ’ as competent 
VMMC/CHAPS practitioners. Adams said 
that the theoretical and practical course 
(plus the in-practice ‘sign-off ’ review) was 
oversubscribed, with 20 doctors on the waiting 
list for the next two training weekends (at the 
time of writing). Up to eight doctors were 
trained in one government facility at a time. 
The training and support service incorporates 
a comprehensive package of services, including 
HIV testing, sexually transmitted infection 
(STI) management, VMMC and condom 
provision. No sexual contact for 6 weeks after 
the procedure and condom use are strongly 
encouraged (circumcision often being 
perceived as an ‘invisible condom’).
Funder exclusion 
barriers removed
A significant development in the lead-up to the 
current public/private partnership was that all 
medical aid schemes (both open and closed) in 
the Metropolitan stable removed all exclusions 
around VMMC (in 2012). Before that, members 
who applied on non-medical grounds were 
automatically exclu ded – a significant barrier 
to HIV prevention efforts. The offer of no out-
of-pocket costs for VMMC services by GPs will 
vastly improve accessibility, with Metropolitan 
Health data suggesting that 35% of VMMCs 
were already being done by GPs, up to 65% 
of circumcisions being conducted as day 
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procedures in hospital. To give some idea of the 
patient savings of the new initiative, a private GP 
visit for the procedure costs around ZAR1 000 
while a private in-hospital procedure could cost 
well into double figures. Over a 10-year time 
horizon, it is estimated that VMMC in high-
prevalence areas will save between ZAR1  650 
and ZAR9 900 per infection prevented. Adams 
said that in Gauteng alone, if 1 000 adult males 
were circum cised, ZAR26.4  million could be 
saved in HIV treatment over 20 years. This 
comprehensively negated arguments that the 
money for VMMC budgets could be better 
used in other HIV prevention strategies. 
‘The very opposite is true: VMMC frees up 
money for other strategies to be enhanced,’ 
he said. Metropolitan Health schemes include 
several closed government schemes such as 
Polmed, Transmed and GEMS, making it the 
largest administrator in the country with three 
million lives covered (followed by Discovery 
and Medscheme). Adams revealed that HIV 
prevalence among Metropolitan Health 
members stood at 6.5%. He appealed to 
other medical schemes to also scrap VMMC 
exclusions on non-medical grounds, saying 
that the benefits of the new project accrued 
to members of any medical scheme and that 
they were a good example of how the private 
and public sectors could work together for the 
benefit of all in the impending National Health 
Insurance.
Government response
Current government VMMC efforts began 
3 years ago after HIV prevention efficacy 
became clear from the original Orange 
Farm pilot study in Gauteng and two other 
sub-Saharan sites. It was initiated after 
comprehensive consultation with all 19 
stakeholders in the South African National 
AIDS Council and discussion on scientific, 
social and cultural issues. It is now official 
policy and part of the 2012 - 2016 National 
Strategic Plan for HIV, STIs and TB. VMMC 
is regarded as a ‘game-changer’ in SA’s HIV 
prevention efforts, and all provinces are 
prioritising efforts to accelerate access.
Asked about the possible inclusion of the 
Prepex, a non-surgical three-ringed device 
that results in the foreskin atrophying and 
falling off after about seven days and is 
currently being piloted by government in 
four provinces, Adams said it was being 
excluded until officially ‘signed off ’. While 
the safety and efficacy of the device were 
very high, ‘we are promoting the surgical 
technique (forceps guided and dorsal slit) – 
the intention is that non-surgical techniques 
will become an option’. Prepex’s greatest 
contribution to the HIV prevention battle 
is that is relatively pain-free, and can be 
prescribed and fitted by a nurse, enabling 
task-shifting down from over-burdened GPs. 
A downside is that a Prepex wound takes 
8 weeks to heal, 2 weeks longer than healing 
after surgical circumcision.
Modelling studies suggest striking impli-
cations of scaling up VMMC in averting 
millions of infections and deaths and saving 
billions of rands in the long run. Adams said 
any further delays would constitute a ‘major 
failure to capitalise on scientific evidence 
to save lives and improve the quality of our 
population’.
A ‘jolly good show’ by 
(and for) CHAPS
CHAPS, a USAID-funded NGO, is a global 
leader in implementing and disseminating 
evidence-based approaches to prevent the 
spread of HIV in southern Africa such as 
efficiency models and professional training. It 
was behind the original sub-Saharan studies 
that proved the efficacy of VMMC. The 
main pillars of the new 3-year public-private 
partnership will include Metropolitan Health 
initially covering the costs of high-quality 
VMMC to over 32 000 men, USAID supplying 
disposable circumcision packs to GPs where 
needed, and CHAPS assisting GPs to set up 
their facilities and address emergencies and 
adverse events, and supporting their accurate 
recording and reporting of VMMC services. 
USAID and CHAPS have also undertaken 
to help create demand and raise awareness of 
GP-provided VMMC services.
Meanwhile Dr Cheryl Baxter, an asso ciate 
researcher at the Centre for the AIDS Program 
of Research in South Africa (CAPRISA) in 
Durban, said there was a paucity of any 
comparable data for HIV prevention in 
women. The only currently available HIV 
prevention options for women were the ABCs 
of Abstinence, Be faithful and Condomise.
Women remain twice  
as vulnerable
Prevention options for women, such as 
microbi cides, long-acting vaginal rings and 
long-acting injectables, while holding promise, 
were not yet available. HIV treatment of an 
infected partner would have an impact on 
HIV prevention for women, but it was not 
something that a woman could control – 
the male partner would have to know his 
HIV status, and if HIV-positive would need 
to be on antiretrovirals (and take them as 
prescribed) for the woman to benefit. Oral 
pre-exposure prophylactics had been shown 
to work in a number of populations (men 
who have sex with men, discordant couples 
and heterosexuals), but again this was not a 
currently available HIV prevention option in 
SA. ‘There might be some data on condom 
scale-up, but most of the condoms distributed 
are male condoms,’ Baxter added.
Women bear a disproportionate burden of 
the HIV epidemic in sub-Saharan Africa 
(SSA), and account for approximately 60% 
of all infections in this region. HIV-infected 
women between the ages of 15 and 24 years 
represent 76% of total cases in that age group. 
The rapid spread of HIV among adolescent 
girls and young women in SA has been 
described as ‘explosive’. A survey conducted 
among high-school students in one KwaZulu-
Natal health district showed that the HIV 
prevalence in girls was six times higher 
than in boys. National, annual, anonymous 
seroprevalence surveys in pregnant women 
using public sector healthcare facilities 
demonstrate that HIV prevalence in SSA 
has increased from 0.8% in 1990 to 30.2% 
in 2010. Several factors contribute to the 
increased vulnerability of young women to 
acquiring HIV in SSA, among them the 
fact that biologically, women appear to be 
more susceptible to acquiring HIV than men. 
According to the US Centers for Disease 
Control and Prevention, the risk of HIV 
infection is 1/2 000 contacts for the male 
partner compared with 1/1 000 contacts for 
the female partner in penile-vaginal sex. 
Women are twice as likely to become infected 
as men after a single sexual encounter.[1]
CAPRISA research associate Dr Cheryl Baxter.
‘If we pursue a downward trend 
in financing AIDS, we see a 
devastating slide backward by 
2020 – an increase in new HIV 
infections and AIDS-related 
deaths and escalating costs 
of controlling the epidemic.’ – 
Moses-Burton
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Downscaling funding 
‘asking for trouble’
The Global Network of People Living with HIV 
(GNP+) last month applauded the conclusions 
of the recent UNAIDS-Lancet Commission 
report, ‘Defeating AIDS – advancing global 
health’, i.e. that failing to continue funding the 
AIDS response sufficiently would have ‘grave 
and immediate consequences’. The Commission 
was tasked with exploring strategies to ensure 
that the vision of the global AIDS movement, 
‘Zero new HIV infections, zero discrimination 
and zero AIDS-related deaths’, could be realised 
in coming decades.  The report stresses that a 
human rights and community mobilisation 
approach has been central to the successes of 
the AIDS response to date, emphasising that 
failure to fund the AIDS response sufficiently, 
particularly the contribution of civil society, 
will have major consequences for continued 
success and sustainability under the sustainable 
development goals.
Suzette Moses-Burton, GNP+ executive 
director, said the report presented two ‘stark and 
contrasting pictures. If we pursue a downward 
trend in financing AIDS, we see a devastating 
slide backward by 2020  – an increase in new 
HIV infections and AIDS-related deaths and 
escalating costs of controlling the epidemic. 
In the alternative picture, with continued 
investment in AIDS over the next 5 years, we 
see HIV transmission at low endemic levels, 
AIDS-related mortality significantly reduced 
and children born HIV free.’
Impressively, the UNAIDS-Lancet Commi-
ssion report makes a strong econo mic argu-
ment for ambitious investment, showing that 
robust financial investment in the HIV response 
now will create significant returns later. Each 
life-year gained in low- and middle-income 
countries produces significant gains in GDP. 
Moses-Burton added: ‘With over 10 million 
people needing antiretroviral drugs today, now 
is not the time to backtrack on funding and 
political commitment. We cannot end the AIDS 
epidemic without that one last push.’
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